OpenBench And ORIC Pharmaceuticals Partner On AI-Driven Small Molecule Discovery To Address Therapeutic Resistance In Cancer
Portfolio Pulse from Benzinga Newsdesk
OpenBench and ORIC Pharmaceuticals have announced a partnership to leverage AI-driven small molecule discovery to tackle therapeutic resistance in cancer. This collaboration aims to enhance drug discovery and development processes.
September 17, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ORIC Pharmaceuticals has partnered with OpenBench to utilize AI for small molecule discovery, focusing on overcoming therapeutic resistance in cancer. This collaboration could accelerate ORIC's drug development pipeline.
The partnership with OpenBench to use AI in drug discovery is likely to enhance ORIC's capabilities in developing cancer therapies. This could lead to advancements in their drug pipeline, potentially increasing investor interest and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90